This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
It’s still cold but the sun has occasionally popped out between the clouds on Day Three at ASH 2017 in Atlanta, Georgia.
It was another long day, with the important clinical oral presentations in the afternoon, CLL-related poster clinical and pre-clinical abstracts in the early evening, meetings talking about new therapies, including targeting micro-RNA and more interviews at ASH (American Society of Hematology) 2017 Annual Meeting in Atlanta Georgia.
The third day saw presentations on the first clinical data on ROR1, several presentations on infections in CLL, combination therapy with checkpoint inhibitors, the accuracy of PET-CT scans for finding Richter’s Transformation, and more on the risks associated with the CLL precursor, monoclonal B-cell lymphocytosis (MBL).
Nothing revolutionary, but we keep learning
Details to follow. You can watch the video below or read the transcription here.
Brian Koffman, MD 12/12/17